{
    "Trade/Device Name(s)": [
        "Illumina MiSeqDx Cystic Fibrosis 139-Variant Assay"
    ],
    "Submitter Information": "Illumina Inc.",
    "510(k) Number": "K124006",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083845"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PFR"
    ],
    "Summary Letter Date": "November 18, 2013",
    "Summary Letter Received Date": "November 19, 2013",
    "Submission Date": "November 18, 2013",
    "Regulation Number(s)": [
        "21 CFR 866.5900"
    ],
    "Regulation Name(s)": [
        "Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection system"
    ],
    "Analyte Class(es)": [
        "genetic molecular"
    ],
    "Analyte(s)": [
        "CFTR gene mutations and variants",
        "139 cystic fibrosis disease-causing mutations/variants",
        "F508del",
        "G542X",
        "G551D",
        "R553X",
        "W1282X",
        "N1303K",
        "R117H",
        "621+1G>T",
        "3849+10kbC>T",
        "R334W",
        "R347P",
        "R347H",
        "A455E",
        "Q493X",
        "S549N",
        "S549R",
        "G85E",
        "R560T",
        "R1162X",
        "M1101K",
        "3659delC",
        "1078delT",
        "394delTT",
        "2183AA>G",
        "2184insA",
        "2184delA",
        "3905insT",
        "3876delA",
        "W846X",
        "R764X",
        "Y1092X",
        "M1V",
        "Q39X",
        "E92X",
        "P67L",
        "E60X",
        "L206W",
        "G178R",
        "711+1G>T",
        "Y122X",
        "D110H",
        "P205S",
        "1336K",
        "R75X",
        "PolyTG/PolyT",
        "S1196X",
        "S341P",
        "Q98X",
        "Q220X",
        "R709X",
        "K710X",
        "S945L",
        "L732X",
        "2347delG",
        "2585delT",
        "E822X",
        "2622+1G>A",
        "E831X",
        "R851X",
        "2711delT",
        "1927P",
        "3007delG",
        "G970R",
        "3121-1G>A",
        "L1065P",
        "L1077P",
        "E1104X",
        "W1204X",
        "G1244E",
        "Q1313X",
        "4209TGTT>AA",
        "4382delA",
        "CFTRdele22,23",
        "1154insTC",
        "1506V",
        "1507V",
        "F508C",
        "S489X",
        "S492F",
        "Q525X",
        "1717-8G>A",
        "Q552X",
        "R560K",
        "1811+1.6kb A>G",
        "E585X",
        "574delA",
        "711+3A>G",
        "711+5 G>A",
        "712-1 G>T",
        "H199Y",
        "852del22",
        "T3381",
        "1213delT",
        "1248+1G>A",
        "1259insA",
        "W401X",
        "S466X (C->G)",
        "S466X (C->A)",
        "L467P",
        "1548delG",
        "1717-1G>A",
        "CFTR dele2, 3",
        "2143delT",
        "1898+1G>A",
        "3120G>A",
        "3120+1G>A",
        "3272-26A>G",
        "R1066C",
        "R1066H",
        "W1089X",
        "R1158X",
        "3659delC"
    ],
    "Specimen Type(s)": [
        "Peripheral whole blood",
        "Genomic DNA isolated from whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Illumina MiSeqDx instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Next generation sequencing",
        "Sequencing by synthesis (SBS)",
        "Library preparation",
        "Sample indexing",
        "Data analysis software"
    ],
    "Methodologies": [
        "Genotyping",
        "Molecular variant detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Reagent",
        "Software",
        "Cartridge",
        "Flow cell",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for Illumina MiSeqDx Cystic Fibrosis 139-Variant Assay using next generation sequencing for CFTR gene mutation detection.",
    "Indications for Use Summary": "Qualitative in vitro diagnostic for simultaneous detection of 139 clinically relevant CFTR gene mutations/variants in genomic DNA from human peripheral whole blood for carrier screening in adults of reproductive age, confirmatory diagnostic testing of newborns and children, and initial diagnosis of suspected cystic fibrosis; results interpreted by board-certified clinical molecular geneticist in conjunction with other laboratory and clinical data; not for use in newborn screening, fetal diagnostic, pre-implantation testing, or as stand-alone diagnostic.",
    "fda_folder": "Immunology"
}